DT01 Rec'd PCT/PTO 1 6 DEC Form PTO-1390-MOD (REV 10-96) U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER 4-32444A TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/510.026 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP 03/03466 2 April 2003 (02.04.03) 3 April 2002 (03.04.02) TITLE OF INVENTION 5-SUBSTITUTED 1,1-DUIXI-1,2M5-THIADIAZOLIDIN-3-ONE DERIVATIVES APPLICANT(S) FOR DO/EO/US COPPOLA ET AL Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. a. is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). 10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ☐ A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.

14. A substitute specification.

16. Other items or information:

15. A change of power of attorney and/or address letter.

U.S. APPLICATION NO. (if known, s 10/510,026	see 37 CFR 1.5)	INTER PC	RNATIONAL APPLICATION NO T/EP 03/03466	D		4-32444A	DOCKET NUMBER	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
17. X The following fees are submitted:								S PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):								13 PIOUSE ONLY
Search Report has been prepared by the EPO or JPO								
International preliminary examination fee paid to USPTO (37 CFR 1.482)								

4.60								
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$790								
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100								
ENTER APPROPRIATE BASIC FEE AMOUNT =							\$	
Surcharge of \$130 for fumonths from the earliest	claimed prio	rity date (37 0	CFR 1.492(e)).)		\$ 130	
CLAIMS Total claims	NUMBE 0		NUMBER EXTR		RA			
Independent claims	0	- 20 = - 3 =		$\frac{x}{x}$	<u> \$ </u>	18 88	\$	<u> </u>
MULTIPLE DEPENDEN				+ +	<u> </u>	300	\$	
TOTAL OF ABOVE CALCULATIONS =							\$ 130	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								
filed (Note 37 CFR 1.9, 1.27, 1.28).							\$	
Processing fee of \$130 for furnishing the English translation later than 20 30 months from							\$ 130	ļ
the earliest claimed priority date (37 CFR 1.492(f)).							\$	1
TOTAL NATIONAL FEE =							\$ 130	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$	
TOTAL FEES ENCLOSED =							\$ 130	
							Amount to be: refunded	\$
							charged	\$
a. A check in the amount of \$ to cover the above fees is enclosed.								
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 to cover the above fees. Two duplicate copies of this form are enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
Send all correspondence to the address associated with Customer No. 001095, which is currently:							2	
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Paivi Kukkola Agent for Applicants Reg. No. 50,499 (862) 778-7875								_

12/23/2004 GFREY1 00000083 190134

10510026

01 FC:1617

130.00 DA